Sengenics offers KREX for use in the discovery, validation, screening and development of new therapeutics through the use of discovery based KREX-based platforms. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Examples of using KREX for discovery of potential therapeutics:
- Discovered protective autoantibodies in NSCLC
- Identified potential autoantibody therapeutics for healthy aging
- Cancer drug discovery with oncogene KREX custom arrays
© 2008 – 2020 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361